Literature DB >> 2328209

The potential of carboxypeptidase G2: antibody conjugates as anti-tumour agents. II. In vivo localising and clearance properties in a choriocarcinoma model.

R G Melton1, F Searle, R F Sherwood, K D Bagshawe, J A Boden.   

Abstract

The in vivo localising and clearance properties of conjugates of the folate-degrading enzyme carboxypeptidase G2 (CPG2) with anti-human chorionic gonadotrophin (W14A) were measured in nude mice bearing CC3 choriocarcinoma xenografts. Conjugates of W14A-F (ab')2 fragment coupled to CPG2 localised in tumour as effectively as native antibody alone but showed lower uptake in other major tissues. The clearance rates of conjugates prepared with intact antibody or F (ab')2 fragment were shown to be up to five-fold faster than for native antibody and two-fold compared to F (ab')2 fragment. Molecular weight analysis of residual conjugate in the blood showed that no degradation of conjugate to its component molecules occurred during circulation. It was concluded that F (ab')2: CPG2 conjugates offered the greatest potential for targeting applications.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2328209      PMCID: PMC1971295          DOI: 10.1038/bjc.1990.92

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

2.  The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies.

Authors:  D PRESSMAN; L KORNGOLD
Journal:  Cancer       Date:  1953-05       Impact factor: 6.860

Review 3.  Recent advances in tumour imaging. Use of radiolabelled antitumour antibodies.

Authors:  R H Begent
Journal:  Biochim Biophys Acta       Date:  1985

4.  Factors that affect antiferritin localization in four rat hepatoma models.

Authors:  R A Rostock; K A Kopher; T W Bauer; J L Klein
Journal:  Cancer Drug Deliv       Date:  1985

5.  Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method.

Authors:  R F Sherwood; R G Melton; S M Alwan; P Hughes
Journal:  Eur J Biochem       Date:  1985-05-02

6.  Fate of an antibody-ricin A chain conjugate administered to normal rats.

Authors:  N R Worrell; A J Cumber; G D Parnell; W C Ross; J A Forrester
Journal:  Biochem Pharmacol       Date:  1986-02-01       Impact factor: 5.858

7.  Enhancement of antitumor activity of 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine and Baker's antifol (triazinate) with carboxypeptidase G1.

Authors:  K K Kalghatgi; B A Moroson; C Horváth; J R Bertino
Journal:  Cancer Res       Date:  1979-09       Impact factor: 12.701

8.  Covalent linkage of carboxypeptidase G2 to soluble dextrans--II. In vivo distribution and fate of conjugates.

Authors:  R G Melton; C N Wiblin; A Baskerville; R L Foster; R F Sherwood
Journal:  Biochem Pharmacol       Date:  1987-01-01       Impact factor: 5.858

9.  Antibody directed enzymes revive anti-cancer prodrugs concept.

Authors:  K D Bagshawe
Journal:  Br J Cancer       Date:  1987-11       Impact factor: 7.640

10.  A human choriocarcinoma xenograft in nude mice; a model for the study of antibody localization.

Authors:  F Searle; J Boden; J C Lewis; K D Bagshawe
Journal:  Br J Cancer       Date:  1981-08       Impact factor: 7.640

View more
  4 in total

1.  Reduced antibody response to streptavidin through site-directed mutagenesis.

Authors:  D L Meyer; J Schultz; Y Lin; A Henry; J Sanderson; J M Jackson; S Goshorn; A R Rees; S S Graves
Journal:  Protein Sci       Date:  2001-03       Impact factor: 6.725

2.  Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice.

Authors:  P Antoniw; C J Springer; K D Bagshawe; F Searle; R G Melton; G T Rogers; P J Burke; R F Sherwood
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

3.  Glucarpidase to combat toxic levels of methotrexate in patients.

Authors:  Jacalyn M Green
Journal:  Ther Clin Risk Manag       Date:  2012-11-22       Impact factor: 2.423

4.  Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.

Authors:  D R Newell; K M Searle; N B Westwood; S S Burtles
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.